79 results on '"D'Silva K"'
Search Results
2. Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
- Author
-
Yeoh, S, Gianfrancesco, M, Lawson-Tovey, S, Hyrich, K, Strangfeld, A, Gossec, L, Carmona, L, Mateus, E, Schafer, M, Richez, C, Hachulla, E, Holmqvist, M, Scire, C, Lorenz, H, Voll, R, Hasseli, R, Jayatilleke, A, Hsu, T, D'Silva, K, Pimentel-Quiroz, V, Vasquez Del Mercado, M, Shinjo, S, Neto, E, Junior, L, De Oliveira E Silva Montandon, A, Pons-Estel, G, Ornella, S, D'Angelo Exeni, M, Velozo, E, Jordan, P, Sirotich, E, Hausmann, J, Liew, J, Jacobsohn, L, Gore-Massy, M, Sufka, P, Grainger, R, Bhana, S, Wallace, Z, Robinson, P, Yazdany, J, Machado, P, Yeoh S. -A., Gianfrancesco M., Lawson-Tovey S., Hyrich K. L., Strangfeld A., Gossec L., Carmona L., Mateus E. F., Schafer M., Richez C., Hachulla E., Holmqvist M., Scire C. A., Lorenz H. -M., Voll R. E., Hasseli R., Jayatilleke A., Hsu T. Y. -T., D'Silva K. M., Pimentel-Quiroz V. R., Vasquez Del Mercado M., Shinjo S. K., Neto E. T. D. R., Junior L. F. D. R., De Oliveira E Silva Montandon A. C., Pons-Estel G. J., Ornella S., D'Angelo Exeni M. E., Velozo E., Jordan P., Sirotich E., Hausmann J. S., Liew J. W., Jacobsohn L., Gore-Massy M., Sufka P., Grainger R., Bhana S., Wallace Z., Robinson P. C., Yazdany J., MacHado P. M., Yeoh, S, Gianfrancesco, M, Lawson-Tovey, S, Hyrich, K, Strangfeld, A, Gossec, L, Carmona, L, Mateus, E, Schafer, M, Richez, C, Hachulla, E, Holmqvist, M, Scire, C, Lorenz, H, Voll, R, Hasseli, R, Jayatilleke, A, Hsu, T, D'Silva, K, Pimentel-Quiroz, V, Vasquez Del Mercado, M, Shinjo, S, Neto, E, Junior, L, De Oliveira E Silva Montandon, A, Pons-Estel, G, Ornella, S, D'Angelo Exeni, M, Velozo, E, Jordan, P, Sirotich, E, Hausmann, J, Liew, J, Jacobsohn, L, Gore-Massy, M, Sufka, P, Grainger, R, Bhana, S, Wallace, Z, Robinson, P, Yazdany, J, Machado, P, Yeoh S. -A., Gianfrancesco M., Lawson-Tovey S., Hyrich K. L., Strangfeld A., Gossec L., Carmona L., Mateus E. F., Schafer M., Richez C., Hachulla E., Holmqvist M., Scire C. A., Lorenz H. -M., Voll R. E., Hasseli R., Jayatilleke A., Hsu T. Y. -T., D'Silva K. M., Pimentel-Quiroz V. R., Vasquez Del Mercado M., Shinjo S. K., Neto E. T. D. R., Junior L. F. D. R., De Oliveira E Silva Montandon A. C., Pons-Estel G. J., Ornella S., D'Angelo Exeni M. E., Velozo E., Jordan P., Sirotich E., Hausmann J. S., Liew J. W., Jacobsohn L., Gore-Massy M., Sufka P., Grainger R., Bhana S., Wallace Z., Robinson P. C., Yazdany J., and MacHado P. M.
- Abstract
Objectives To investigate factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy (IIM). Methods Demographic data, clinical characteristics and COVID-19 outcome severity of adults with IIM were obtained from the COVID-19 Global Rheumatology Alliance physician-reported registry. A 3-point ordinal COVID-19 severity scale was defined: (1) no hospitalisation, (2) hospitalisation (and no death) and (3) death. ORs were estimated using multivariable ordinal logistic regression. Sensitivity analyses were performed using a 4-point ordinal scale: (1) no hospitalisation, (2) hospitalisation with no oxygen (and no death), (3) hospitalisation with oxygen/ventilation (and no death) and 4) death. Results Of 348 patients, 48% were not hospitalised, 39% were hospitalised (and did not die) and 13% died. Older age (OR=1.59/decade, 95% CI 1.31 to 1.91), high disease activity (OR=3.50, 95% CI 1.25 to 9.83; vs remission), ≥2 comorbidities (OR=2.63, 95% CI 1.39 to 4.98; vs none), prednisolone-equivalent dose >7.5 mg/day (OR=2.40, 95% CI 1.09 to 5.28; vs no intake) and exposure to rituximab (OR=2.71, 95% CI 1.28 to 5.72; vs conventional synthetic disease-modifying antirheumatic drugs only) were independently associated with severe COVID-19. In addition to these variables, in the sensitivity analyses, male sex (OR range: 1.65-1.83; vs female) was also significantly associated with severe outcomes, while COVID-19 diagnosis after 1 October 2020 (OR range: 0.51-0.59; vs on/before 15 June 2020) was significantly associated with less severe outcomes, but these associations were not significant in the main model (OR=1.57, 95% CI 0.95 to 2.59; and OR=0.61, 95% CI 0.37 to 1.00; respectively). Conclusions This is the first large registry data on outcomes of COVID-19 in people with IIM. Older age, male sex, higher comorbidity burden, high disease activity, prednisolone-equivalent dose >7.5 mg/day and rituximab exposure were associated with severe COVID-19. These
- Published
- 2022
3. OP0139 EFFICACY AND SAFETY OF ABBV-599 HIGH DOSE (ELSUBRUTINIB 60 MG AND UPADACITINIB 30 MG) AND UPADACITINIB MONOTHERAPY FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
- Author
-
Merrill, J. T., primary, Tanaka, Y., additional, D’cruz, D., additional, Vila, K., additional, Siri, D., additional, Zeng, X., additional, D’silva, K., additional, Cheng, L., additional, Sornasse, T., additional, Doan, T., additional, Kruzikas, D., additional, and Friedman, A., additional
- Published
- 2023
- Full Text
- View/download PDF
4. POS1108 EFFICACY OF UPADACITINIB IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IN EARLY VERSUS ESTABLISHED DISEASE
- Author
-
Navarro-Compán, V., primary, Van den Bosch, F., additional, Sampaio-Barros, P. D., additional, Ganz, F., additional, Biljan, A., additional, Duan, Y., additional, D’silva, K., additional, Wung, P., additional, Ostor, A., additional, and Ramiro, S., additional
- Published
- 2023
- Full Text
- View/download PDF
5. POS1498 COMORBIDITIES AND SAFETY EVENTS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
- Author
-
Krueger, W., primary, Feger, D., additional, Friedman, A., additional, Doan, T., additional, and D’silva, K., additional
- Published
- 2023
- Full Text
- View/download PDF
6. POS0250 PLACEBO-CONTROLLED EFFICACY AND SAFETY OF UPADACITINIB THROUGH ONE YEAR IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
- Author
-
Van den Bosch, F., primary, Deodhar, A., additional, Poddubnyy, D., additional, Maksymowych, W. P., additional, Van der Heijde, D., additional, Kim, T. H., additional, Kishimoto, M., additional, Baraliakos, X., additional, Duan, Y., additional, D’silva, K., additional, Wung, P., additional, and Song, I. H., additional
- Published
- 2023
- Full Text
- View/download PDF
7. Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody
- Author
-
Sclafani, A., D’Silva, K. M., Little, B. P., Miloslavsky, E. M., Locascio, J. J., Sharma, A., and Montesi, S. B.
- Published
- 2019
- Full Text
- View/download PDF
8. Efficacité et tolérance d’upadacitinib chez des patients atteints de spondylarthrite ankylosante et ayant eu une intolérance et/ou un manque d’efficacité lors d’un traitement antérieur par biologique : analyse en sous-groupes
- Author
-
Baraliakos, X., primary, Ganz, F., additional, Kameda, H., additional, Walsh, J.A., additional, Jain, M., additional, D'silva, K., additional, Wung, P., additional, Bu, X., additional, Stigler, J., additional, Goupille, P., additional, and Van Der Heijde, D., additional
- Published
- 2022
- Full Text
- View/download PDF
9. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
- Author
-
Sparks, J, Wallace, Z, Seet, A, Gianfrancesco, M, Izadi, Z, Hyrich, K, Strangfeld, A, Gossec, L, Carmona, L, Mateus, E, Lawson-Tovey, S, Trupin, L, Rush, S, Katz, P, Schmajuk, G, Jacobsohn, L, Wise, L, Gilbert, E, Duarte-Garcia, A, Valenzuela-Almada, M, Pons-Estel, G, Isnardi, C, Berbotto, G, Hsu, T, D'Silva, K, Patel, N, Kearsley-Fleet, L, Schafer, M, Ribeiro, S, Al Emadi, S, Tidblad, L, Scire, C, Raffeiner, B, Thomas, T, Flipo, R, Avouac, J, Seror, R, Bernardes, M, Cunha, M, Hasseli, R, Schulze-Koops, H, Muller-Ladner, U, Specker, C, De Souza, V, Da Mota, L, Gomides, A, Dieude, P, Nikiphorou, E, Kronzer, V, Singh, N, Ugarte-Gil, M, Wallace, B, Akpabio, A, Thomas, R, Bhana, S, Costello, W, Grainger, R, Hausmann, J, Liew, J, Sirotich, E, Sufka, P, Robinson, P, Machado, P, Yazdany, J, Sparks J. A., Wallace Z. S., Seet A. M., Gianfrancesco M. A., Izadi Z., Hyrich K. L., Strangfeld A., Gossec L., Carmona L., Mateus E. F., Lawson-Tovey S., Trupin L., Rush S., Katz P., Schmajuk G., Jacobsohn L., Wise L., Gilbert E. L., Duarte-Garcia A., Valenzuela-Almada M. O., Pons-Estel G. J., Isnardi C. A., Berbotto G. A., Hsu T. Y. -T., D'Silva K. M., Patel N. J., Kearsley-Fleet L., Schafer M., Ribeiro S. L. E., Al Emadi S., Tidblad L., Scire C. A., Raffeiner B., Thomas T., Flipo R. -M., Avouac J., Seror R., Bernardes M., Cunha M. M., Hasseli R., Schulze-Koops H., Muller-Ladner U., Specker C., De Souza V. A., Da Mota L. M. H., Gomides A. P. M., Dieude P., Nikiphorou E., Kronzer V. L., Singh N., Ugarte-Gil M. F., Wallace B., Akpabio A., Thomas R., Bhana S., Costello W., Grainger R., Hausmann J. S., Liew J. W., Sirotich E., Sufka P., Robinson P. C., MacHado P. M., Yazdany J., Sparks, J, Wallace, Z, Seet, A, Gianfrancesco, M, Izadi, Z, Hyrich, K, Strangfeld, A, Gossec, L, Carmona, L, Mateus, E, Lawson-Tovey, S, Trupin, L, Rush, S, Katz, P, Schmajuk, G, Jacobsohn, L, Wise, L, Gilbert, E, Duarte-Garcia, A, Valenzuela-Almada, M, Pons-Estel, G, Isnardi, C, Berbotto, G, Hsu, T, D'Silva, K, Patel, N, Kearsley-Fleet, L, Schafer, M, Ribeiro, S, Al Emadi, S, Tidblad, L, Scire, C, Raffeiner, B, Thomas, T, Flipo, R, Avouac, J, Seror, R, Bernardes, M, Cunha, M, Hasseli, R, Schulze-Koops, H, Muller-Ladner, U, Specker, C, De Souza, V, Da Mota, L, Gomides, A, Dieude, P, Nikiphorou, E, Kronzer, V, Singh, N, Ugarte-Gil, M, Wallace, B, Akpabio, A, Thomas, R, Bhana, S, Costello, W, Grainger, R, Hausmann, J, Liew, J, Sirotich, E, Sufka, P, Robinson, P, Machado, P, Yazdany, J, Sparks J. A., Wallace Z. S., Seet A. M., Gianfrancesco M. A., Izadi Z., Hyrich K. L., Strangfeld A., Gossec L., Carmona L., Mateus E. F., Lawson-Tovey S., Trupin L., Rush S., Katz P., Schmajuk G., Jacobsohn L., Wise L., Gilbert E. L., Duarte-Garcia A., Valenzuela-Almada M. O., Pons-Estel G. J., Isnardi C. A., Berbotto G. A., Hsu T. Y. -T., D'Silva K. M., Patel N. J., Kearsley-Fleet L., Schafer M., Ribeiro S. L. E., Al Emadi S., Tidblad L., Scire C. A., Raffeiner B., Thomas T., Flipo R. -M., Avouac J., Seror R., Bernardes M., Cunha M. M., Hasseli R., Schulze-Koops H., Muller-Ladner U., Specker C., De Souza V. A., Da Mota L. M. H., Gomides A. P. M., Dieude P., Nikiphorou E., Kronzer V. L., Singh N., Ugarte-Gil M. F., Wallace B., Akpabio A., Thomas R., Bhana S., Costello W., Grainger R., Hausmann J. S., Liew J. W., Sirotich E., Sufka P., Robinson P. C., MacHado P. M., and Yazdany J.
- Abstract
Objective To investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA). Methods We analysed the COVID-19 Global Rheumatology Alliance physician registry (from 24 March 2020 to 12 April 2021). We investigated b/tsDMARD use for RA at the clinical onset of COVID-19 (baseline): abatacept (ABA), rituximab (RTX), Janus kinase inhibitors (JAKi), interleukin 6 inhibitors (IL-6i) or tumour necrosis factor inhibitors (TNFi, reference group). The ordinal COVID-19 severity outcome was (1) no hospitalisation, (2) hospitalisation without oxygen, (3) hospitalisation with oxygen/ventilation or (4) death. We used ordinal logistic regression to estimate the OR (odds of being one level higher on the ordinal outcome) for each drug class compared with TNFi, adjusting for potential baseline confounders. Results Of 2869 people with RA (mean age 56.7 years, 80.8% female) on b/tsDMARD at the onset of COVID-19, there were 237 on ABA, 364 on RTX, 317 on IL-6i, 563 on JAKi and 1388 on TNFi. Overall, 613 (21%) were hospitalised and 157 (5.5%) died. RTX (OR 4.15, 95% CI 3.16 to 5.44) and JAKi (OR 2.06, 95% CI 1.60 to 2.65) were each associated with worse COVID-19 severity compared with TNFi. There were no associations between ABA or IL6i and COVID-19 severity. Conclusions People with RA treated with RTX or JAKi had worse COVID-19 severity than those on TNFi. The strong association of RTX and JAKi use with poor COVID-19 outcomes highlights prioritisation of risk mitigation strategies for these people.
- Published
- 2021
10. POS1234 DMARD DISRUPTION, INCREASED DISEASE ACTIVITY, AND PROLONGED SYMPTOM DURATION AFTER ACUTE COVID-19 AMONG PATIENTS WITH RHEUMATIC DISEASE: A PROSPECTIVE STUDY
- Author
-
DI Iorio, M., primary, Cook, C., additional, Vanni, K., additional, Patel, N., additional, D’silva, K., additional, Fu, X., additional, Wang, J., additional, Prisco, L., additional, Kowalski, E., additional, Zaccardelli, A., additional, Martin, L., additional, Qian, G., additional, Hsu, T., additional, Wallace, Z., additional, and Sparks, J., additional
- Published
- 2022
- Full Text
- View/download PDF
11. OP0252 FACTORS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHY: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRY
- Author
-
Yeoh, S. A., primary, Gianfrancesco, M., additional, Lawson-Tovey, S., additional, Hyrich, K., additional, Strangfeld, A., additional, Gossec, L., additional, Carmona, L., additional, Mateus, E., additional, Schaefer, M., additional, Richez, C., additional, Hachulla, E., additional, Holmqvist, M., additional, Scirè, C. A., additional, Hasseli, R., additional, Jayatilleke, A., additional, Hsu, T., additional, D’Silva, K., additional, Pimentel-Quiroz, V., additional, Vasquez del Mercado, M., additional, Katsuyuki Shinjo, S., additional, Reis Neto, E., additional, Rocha, L., additional, Montandon, A. C. D. O. E. S., additional, Jordan, P., additional, Sirotich, E., additional, Hausmann, J., additional, Liew, J., additional, Jacobsohn, L., additional, Gore-Massy, M., additional, Sufka, P., additional, Grainger, R., additional, Bhana, S., additional, Wallace, Z., additional, Robinson, P., additional, Yazdany, J., additional, and Machado, P., additional
- Published
- 2022
- Full Text
- View/download PDF
12. OP0286 CHARACTERISTICS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE (COVID-19 GRA)
- Author
-
Ugarte-Gil, M. F., primary, Alarcon, G. S., additional, Seet, A., additional, Izadi, Z., additional, Reategui Sokolova, C., additional, Clarke, A. E., additional, Wise, L., additional, Pons-Estel, G., additional, Santos, M. J., additional, Bernatsky, S., additional, Mathias, L., additional, Lim, N., additional, Sparks, J., additional, Wallace, Z., additional, Hyrich, K., additional, Strangfeld, A., additional, Gossec, L., additional, Carmona, L., additional, Mateus, E., additional, Lawson-Tovey, S., additional, Trupin, L., additional, Rush, S., additional, Schmajuk, G., additional, Katz, P., additional, Jacobsohn, L., additional, Al Emadi, S., additional, Gilbert, E., additional, Duarte-Garcia, A., additional, Valenzuela-Almada, M., additional, Hsu, T., additional, D’silva, K., additional, Serling-Boyd, N., additional, Dieudé, P., additional, Nikiphorou, E., additional, Kronzer, V., additional, Singh, N., additional, Wallace, B., additional, Akpabio, A., additional, Thomas, R., additional, Bhana, S., additional, Costello, W., additional, Grainger, R., additional, Hausmann, J., additional, Liew, J., additional, Sirotich, E., additional, Sufka, P., additional, Robinson, P., additional, Machado, P., additional, Gianfrancesco, M., additional, and Yazdany, J., additional
- Published
- 2021
- Full Text
- View/download PDF
13. POS1174 HYPERINFLAMMATION AND CLINICAL OUTCOMES FOR PATIENTS WITH SYSTEMIC RHEUMATIC DISEASES HOSPITALIZED FOR COVID-19: A COMPARATIVE COHORT STUDY
- Author
-
Hsu, T., primary, D’silva, K., additional, Serling-Boyd, N., additional, Wang, J., additional, Mueller, A., additional, Fu, X., additional, Prisco, L., additional, Martin, L., additional, Vanni, K., additional, Zaccardelli, A., additional, Cook, C., additional, Choi, H., additional, Zhang, Y., additional, Gravallese, E., additional, Wallace, Z., additional, and Sparks, J., additional
- Published
- 2021
- Full Text
- View/download PDF
14. OP0288 MACHINE LEARNING ALGORITHMS TO PREDICT COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME IN PATIENTS WITH RHEUMATIC DISEASES: RESULTS FROM THE GLOBAL RHEUMATOLOGY ALLIANCE PROVIDER REGISTRY
- Author
-
Izadi, Z., primary, Gianfrancesco, M., additional, Hyrich, K., additional, Strangfeld, A., additional, Gossec, L., additional, Carmona, L., additional, Mateus, E., additional, Lawson-Tovey, S., additional, Trupin, L., additional, Rush, S., additional, Schmajuk, G., additional, Jacobsohn, L., additional, Katz, P., additional, Al Emadi, S., additional, Wise, L., additional, Gilbert, E., additional, Valenzuela-Almada, M., additional, Duarte-Garcia, A., additional, Sparks, J., additional, Hsu, T., additional, D’silva, K., additional, Serling-Boyd, N., additional, Bhana, S., additional, Costello, W., additional, Grainger, R., additional, Hausmann, J., additional, Liew, J., additional, Sirotich, E., additional, Sufka, P., additional, Wallace, Z., additional, Machado, P., additional, Robinson, P., additional, and Yazdany, J., additional
- Published
- 2021
- Full Text
- View/download PDF
15. OP0006 ASSOCIATIONS OF BASELINE USE OF BIOLOGIC OR TARGETED SYNTHETIC DMARDS WITH COVID-19 SEVERITY IN RHEUMATOID ARTHRITIS: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE
- Author
-
Sparks, J., primary, Wallace, Z., additional, Seet, A., additional, Gianfrancesco, M., additional, Izadi, Z., additional, Hyrich, K., additional, Strangfeld, A., additional, Gossec, L., additional, Carmona, L., additional, Mateus, E., additional, Lawson-Tovey, S., additional, Trupin, L., additional, Rush, S., additional, Schmajuk, G., additional, Katz, P., additional, Jacobsohn, L., additional, Al Emadi, S., additional, Wise, L., additional, Gilbert, E., additional, Duarte-Garcia, A., additional, Valenzuela-Almada, M., additional, Hsu, T., additional, D’silva, K., additional, Serling-Boyd, N., additional, Dieudé, P., additional, Nikiphorou, E., additional, Kronzer, V., additional, Singh, N., additional, Ugarte-Gil, M. F., additional, Wallace, B., additional, Akpabio, A., additional, Thomas, R., additional, Bhana, S., additional, Costello, W., additional, Grainger, R., additional, Hausmann, J., additional, Liew, J., additional, Sirotich, E., additional, Sufka, P., additional, Robinson, P., additional, Machado, P., additional, and Yazdany, J., additional
- Published
- 2021
- Full Text
- View/download PDF
16. OP0247 PERSISTENT PREMATURE MORTALITY GAP IN IDIOPATHIC INFLAMMATORY MYOPATHY: A GENERAL POPULATION-BASED COHORT STUDY
- Author
-
D’silva, K., primary, Lu, L., additional, Ogdie, A., additional, Aviña, A., additional, and Choi, H., additional
- Published
- 2020
- Full Text
- View/download PDF
17. OP0015 SEX-SPECIFIC U-SHAPED RELATIONSHIP BETWEEN SERUM URATE AND MORTALITY IN THE UNITED STATES GENERAL POPULATION
- Author
-
D’silva, K., primary, Yokose, C., additional, Lu, L., additional, Zhang, Y., additional, and Choi, H., additional
- Published
- 2020
- Full Text
- View/download PDF
18. Arthritis and use of hydroxychloroquine associated with a decreased risk of macrophage activation syndrome among adult patients hospitalized with systemic lupus erythematosus
- Author
-
Cohen, E M, primary, D’Silva, K, additional, Kreps, D, additional, Son, M B, additional, and Costenbader, K H, additional
- Published
- 2018
- Full Text
- View/download PDF
19. EFFICACY OF UPADACITINIB IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IN EARLY VERSUS ESTABLISHED DISEASE.
- Author
-
Navarro-Compán, V., Van den Bosch, F., Sampaio-Barros, P. D., Ganz, F., Biljan, A., Duan, Y., D'silva, K., Wung, P., Ostor, A., and Ramiro, S.
- Published
- 2023
- Full Text
- View/download PDF
20. PLACEBO-CONTROLLED EFFICACY AND SAFETY OF UPADACITINIB THROUGH ONE YEAR IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS.
- Author
-
Van den Bosch, F., Deodhar, A., Poddubnyy, D., Maksymowych, W. P., Van der Heijde, D., Kim, T. H., Kishimoto, M., Baraliakos, X., Duan, Y., D'silva, K., Wung, P., and Song, I. H.
- Published
- 2023
- Full Text
- View/download PDF
21. EFFICACY AND SAFETY OF ABBV-599 HIGH DOSE (ELSUBRUTINIB 60 MG AND UPADACITINIB 30 MG) AND UPADACITINIB MONOTHERAPY FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
- Author
-
Merrill, J. T., Tanaka, Y., D'cruz, D., Vila, K., Siri, D., Zeng, X., D'silva, K., Cheng, L., Sornasse, T., Doan, T., Kruzikas, D., and Friedman, A.
- Published
- 2023
- Full Text
- View/download PDF
22. COMORBIDITIES AND SAFETY EVENTS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS.
- Author
-
Krueger, W., Feger, D., Friedman, A., Doan, T., and D'silva, K.
- Published
- 2023
- Full Text
- View/download PDF
23. Testing the discriminatory power of factors of Internal Auditing effectiveness: Sorting the wheat from the chaff
- Author
-
UCL - SSH/ILSM - Louvain School of Management Research Institute, Louvain School of Management - Accounting & Finance, Lenz, Rainer, Sarens, Gerrit, D'Silva, K., UCL - SSH/ILSM - Louvain School of Management Research Institute, Louvain School of Management - Accounting & Finance, Lenz, Rainer, Sarens, Gerrit, and D'Silva, K.
- Published
- 2012
24. 246 Preoperative chemoradiotherapy for rectal cancer
- Author
-
D'Silva, K., primary, Gopaul, D., additional, Colquhoun, P., additional, Kanjeekal, S., additional, and Fung, K., additional
- Published
- 2006
- Full Text
- View/download PDF
25. 'When I first got it, I wanted to throw it off a cliff': the challenges and benefits of learning AAC technologies as described by adults who use AAC.
- Author
-
Rackensperger T, Krezman C, McNaughton D, Williams MB, and D'Silva K
- Abstract
Seven individuals (aged 21-41 years) with cerebral palsy and who used speech generating augmentative and alternative communication (AAC) devices participated in a focus group discussion on the benefits and challenges of learning AAC technologies. The focus group was conducted on the Internet over a 9-week period. Five major themes emerged from the discussion: (a) selection of an AAC device; (b) knowledge and skills needed to use AAC technologies; (c) instruction and practice activities; (d) assessment of skill acquisition; and (e) advice to others. Participants reported that a consumer-driven assessment approach, which included the opportunity to discuss options with other individuals who used AAC, was key to the selection of an appropriate device. Participants identified a wide variety of important supports to learning how to make effective use of AAC technologies, including text and technological supports, individual exploration, learning from professionals, drill and practice, learning from peers, and opportunities for functional use in the community. For the participants, successful use of AAC technology was best assessed by functional use in the community. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
26. Cetuximab-related tumor lysis syndrome in metastatic colon carcinoma.
- Author
-
Krishnan G, D'Silva K, and Al-Janadi A
- Published
- 2008
27. External auditor independence: selected group perceptions
- Author
-
D'Silva, K.
- Subjects
HG - Abstract
The professional independence of external auditors is fundamental to the auditing profession. Thus, it is important that auditors are not only independent in fact, but that they are also seen to be independent - i. e. independent in aPRearance. In that light, it is clear that external auditor independence (EAI) is a perceptual issue. Yet there is a marked lack of empirical research done with a view to determine how users of audited accounts perceive EAI, or to contrast such views with comparable ones held by external auditors themselves. Thus, the major objective of the research is to empirically examine how relevant groups see EAI within specified audit situations. The research examines how three groups of users of audited statements (bankers, credit managers and internal auditors - the user groups) and sets of external auditors (who issue audit reports - the issuer groups), see EAI in circumstances described in specific audit situations. This is the primary context of the empirical research. An appropriate questionnaire was developed and used as the research instrument because of its natural accord with the Brunswick Lens Model approach to perceptual examinations. The facts specified in each of the twenty situations were cues upon which judgement of EAI, was made by judges (the questionnaire respondents). Thus, the empirical chapters consider: 1. Areas of concern with EAI 2. Significant perceptual differences: a) between each user group and the issuer group b) within two sub-groups of the issuer group 3. Possible explanations for differences by examining: a) the dimensions underlying group views of EAI b) the importance attached by groups to EAI cues c) the pattern between bio-data and views on EAI main findings indicate, within an EAI context: 1. Significant differences of perception between the issuer group and each of the three user groups. 2. Generally non-significant differences of perception within the external auditor group. 3. Each group having its own unique set of underlying (factor or dimensional) constructs. 4. The cues (facts) contained in audit environments are of consequence in explaining such group differences. 5. Personal group characteristics (attributes) do not appear to be very helpful in explaining group views.
28. Nephroprotective potential of Graptophyllum pictum against renal injury induced by gentamicin
- Author
-
Srinivasan, K. K., Mathew, J. E., A D’silva, K. J., RICHARD LOBO, and Kumar, N.
29. A theoretical and empirical analysis of governance disclosure quality within Pakistani listed banks : evaluations of revisions consequent to the Pakistani Corporate Governance Codes 2012 and 2017
- Author
-
Muhammad, Atta, D'Silva, K., and Ridley, J.
- Abstract
Research Background - Trust is the focal point of this thesis. It is an integral part of capitalist economies and, therefore, corporate governance. The relationship of trust serves as a bond and brings together different individuals of diverse interests to work collectively to fulfil their objectives. But in the last two decades, this relationship of trust has been badly shaken due to various reasons. To restore the bond of trust, policymakers in different jurisdictions have developed and introduced various policies and procedures. Such effort has been made by the Security and Exchange Commission of Pakistan (SECP), as it developed and implemented the country first Corporate Governance Code in 2002 and revised them twice in 2012 and 2017. But making rules, regulations, procedures, and policies are only one aspect of restoring the relationship of trust. The rules can be made very strong and fanciful, but only the implementation, compliance, and actions make them effective. Therefore, this doctoral research thesis empirically examines and evaluates the SECP Corporate Governance Code and tries to find out to what degree the SECP has succeeded in restoring the relationship of trust. Correspondingly, the doctoral research thesis increases awareness by empirically examining the benefits of compliance and implementation of regulatory frameworks with a truthful spirit and sound Corporate Governance practices among key stakeholders. Research Setting -Theoretically, the research is focused on the overall domain of Corporate Governance. In empirical and geographic terms, it is located across the listed Pakistani banking sector, during years prior to and post the introduction of the SECP revised Corporate Governance Codes, 2012 and 2017. The research constructs a conceptual model by using the two most important theories - Signalling Theory and Stakeholder Trust Theory and seeks provide a comprehensive theoretical explanation using sets of hypotheses that are employed as a theoretical foundation for further empirical investigations Research Purpose - A review of the relevant literature more than suggests a literature gap in terms of the effectiveness of board monitoring and governance disclosure quality. It is this gap that motivates and gives basis to the research. Additionally, the recent revisions of the current relevant Corporate Governance Code both provoke and invite an empirical examination of the effect (if any) on governance disclosure quality made by the identified sector over relevant years to determine changes in such quality - those possibly triggered by the identified revised code. In so doing, appropriate linked knowledge is also generated. Research Design/Methodology/Approach - Significant consideration is given to the design and methodology employed for the research. Thus, appropriate decisions are made concerning the intended research philosophy (primarily positivist), approach (essentially deductive), method (significantly quantitative and mono methodical), strategy (archival), time horizon (longitudinal, as the construction of disclosure index and measurement process, is very time consuming, a longer sample period as uses in time series analysis is not feasible). The actual research set of banks represents 100% of the listed Pakistani banks uses to examine the impact of revisions of the SECP code across three-time periods. Regression analyses are used to test the relationship between variables. The study develops a Governance Disclosure Quality Index (GQI) using guidelines identified by the United Nation Conference on Trade and Development (UNCTAD, 2006), OECD Principles, 2015, Basel Requirements for Corporate Governance of Banks, 2015, Global Reporting Initiative (GRI) Standards, 2018 and provisions of the SECP Corporate Governance Code and other key previous literature. Research Findings/Outcomes - The research's main findings show that the Governance Disclosure Quality of the Pakistani listed banks in their annual were reports enhanced after each revision of the SECP Corporate Governance Code. However, better board and audit committee composition and function through enhanced SECP Corporate Governance Codes did not significantly impact governance disclosure quality. The main reason for this non-significant relationship appears to be that Pakistani listed banks have not complied with the board and audit committee structural guidelines of the SECP CG Code with spirit and instead used the tick box approach. Research Limitations - The research has used data from only one sector, Pakistani listed banks. This has been done because the financial sector has special regulations regarding Corporate Governance and disclosure, and it is not wise to compare this sector with others. Either we can exclude the financial sector from sample selection or only use the data from that particular sector. Research Contribution to Knowledge - The contribution and value of this research can be mainly divided into four areas. Firstly, it focuses on the banking sector in emerging markets. Many studies have been done on industrial firms in developed countries. This research takes a different view and provides empirical evidence within the Pakistani environment. Secondly, the study provides a comprehensive theoretical explanation using two distinct but relevant theories - Signalling Theory and Stakeholder Trust Theory. Thirdly, this is the first study that primarily evaluates and examines the impact of the SECP Code's revisions on governance disclosure quality in Pakistani listed banks. The input-mediator-output approach examines how banks' financial position mediates the relationship between board and audit committee characteristics and governance disclosure quality. The research also empirically confirms that the SECP code's revisions act as a moderator, and the above-mentioned relationship is stronger after each revision. By so doing the study contributes to bringing increased awareness of sound Corporate Governance practice among key stakeholders. Fourthly, the research provides recommendations to enhance governance disclosure quality. It describes the corporate board in the Pakistani listed banking context using inclusive board composition and functioning measures. The findings help policymakers and regulators assess the adequacy of the Board of Directors' guidelines in the terms of SECP Corporate Governance Code of Pakistan. Originality/Value - In contrast with several previous studies in Corporate Governance domains, which mainly examine and compare Corporate Governance practices between developing and developed countries (to highlight the importance and bring awareness among stakeholders) in terms of sound Corporate Governance. This research examines and compares Corporate Governance practices within a single country, but across three different time periods (each time period had different corporate governance practices in Pakistani listed banks due to revisions of the SECP Corporate Governance Code, 2012 and 2017) to increase awareness of sound Corporate Governance practices (proxies of governance disclosure quality) among stakeholders. Indeed, when stakeholders are made aware of the importance of sound Corporate Governance, they tend to demand more of it.
- Published
- 2022
- Full Text
- View/download PDF
30. Non-Executive Directors and corporate strategy : theory and exploratory empirical insights from FTSE 350 Companies
- Author
-
Lisson, Muriel, D'Silva, K., and Lloyd, B.
- Abstract
The objective of this thesis is to provide exploratory, theoretical, and new empirical insights into Non-Executive Directors' (NEDs) contribution to corporate strategy within London Stock Exchange's largest 350 companies (FTSE 350), all of which have the same legal and regulatory duties. This research deploys an interpretivist philosophy, responding to four fundamental research questions, with appropriate ontological, epistemological, and axiological considerations surrounding NEDs' corporate strategy oversight. This research uniquely applies the constructs of Institutional Theory in conjunction with Instrumental Stakeholder Theory, whilst the empirical examination of NEDs' oversight contributions into corporate strategy capabilities is considered in terms of their constituents: 'Shaping', 'Conducting' and 'Deciding' appropriate strategies. The research itself employed a mixed-method, parallel-layered, theoretically informed, content and descriptive analysis, including cross-sectional financial data analysis performed during 2019-2020, targeting data covering FTSE 350 NEDs' strategic oversight role. The theoretical and empirical research provides original and valuable insights into NED's involvement in corporate strategy. Specifically, it produced no observable evidence of the existence of any Corporate Strategy Committees involving FTSE 350 NEDs. The explicit and implicit contributions to knowledge and policies arising from the research outcomes is the identification of a need for NEDs to show greater strategic leadership and become directly involved in a proposed Corporate Strategy Committee. This would afford the board greater strategic oversight to deliver more meaningful, measurable statements on the long-term sustainability of their company, i.e., over 5 to 10 years, within their Strategic Report. This research identifies the need for further research into theoretical and methodological issues relating to FTSE 350 NEDs' strategic oversight role.
- Published
- 2022
- Full Text
- View/download PDF
31. Features affecting the quality of sustainability reporting : theoretically-informed insights and empirical evidence from the Global Fortune 100 (2011-2015)
- Author
-
Abd El-Rahman, Noha, D'Silva, K., and Rashwan, M.
- Subjects
658.4 - Abstract
Sound Corporate Governance (CG) requires business entities to take responsible regard for the equitable interests of all stakeholders and appropriately align their individual concerns. Given that society generally is one significant stakeholder, it then becomes relevant to determine how such entities take regard for and report upon the social and environmental issues that currently threaten the sustainability of our globe. Accordingly, this research focuses on such sustainability issues and how they are reported, through Sustainability Reporting (SR). Verifying corporate social and environmental activities to stakeholders through Sustainability Reporting (SR) tends to gain and maintain corporate social Legitimacy and continuity in the market. This is because, SR is an effective and efficient tool for measuring and communicating the corporate social and environmental performance, in conjunction with its economic performance to stakeholders. Despite the critical importance of Sustainability Reporting, academics and professionals claim that the Quality of Sustainability Reporting is poor. Given this poor quality, it is recognized that several Sustainability Reports do not fulfill the needs of stakeholders. Consequently, based on the theoretical foundation of Legitimacy Theory and relevant literature, this research aims at hypothesizing and testing the effect of four features on the Quality of Sustainability Reporting (QSR). These features are Adherence to Regulation (ATR), External Assurance of Report (ASR), Independence of Board (IOB) and Type of Information (TOI). QSR is determined via the Index of the Global Reporting Initiatives (GRI). The GRI is regarded as the international proxy for Sustainability Reporting. Its Index identifies the performance indicators that should be included within the Sustainability Report, in order to fulfill the needs of stakeholders. The relationship between these features and QSR are tested/evaluated within 500 reports. These 500 are the Sustainability Reports of the Global Fortune 100 (G100) companies over the five-year period 2011-2015. Employing an ordinal dependent variable (QSR), the research applies an Ordinal, Logistic Regression (OLS) to statistically test hypothesized relationships. The SPSS statistical software package is used to implement that regression and to statistically analyze the collected data. The research concludes that Adherence To Regulations, External Assurance of Report, Independence of Board and Type of Information significantly affect, (representing 37.1% - 41% of the change in) the Quality of Sustainability Reporting. It also concludes that, Adherence to Regulations and External Assurance of Report have an Extremely Significant and Positive, relationship with the Quality of Sustainability Reporting. Moreover; there is a Significant and Positive, relationship between the Type of Information and Quality of Sustainability Reporting. Regarding the Independence of Board, two main phenomena are identified from the empirical results. The results identify that, there is a Non-significant relationship between Independence of Board Members and the Quality of Sustainability Reporting. However; there is a Significant, Positive, relationship between the Independence of Board Chair and the Quality of Sustainability Reporting. Therefore, Adherence to Regulations, External Assurance of Report, Independence of Board Chair and Type of Information are significant influencing factors that should be seriously considered by reporting firms in order to improve the Quality of Sustainability Reporting.
- Published
- 2019
- Full Text
- View/download PDF
32. Using macroeconomic variables in the prediction of stock market indices : a theoretical and empirical assessment within BRICS and selected developed economies
- Author
-
Ouattara, B. S., D'Silva, K., Xiao, L., and Barber, S.
- Subjects
657 - Abstract
The prediction of stock market indices and issues/questions associated with such predictions, have been a challenge for several academics, business analysts and financial researchers for many years. In the main, these challenges have been addressed within developed economies; statistically using appropriately determined macroeconomic independent variables. However, much less attention has been directed to the use of such variables within developing economies. This sparse attention forms the research background (Chapter I) and provides partial justification for the research itself. Thus, the research comparatively focuses on both, certain developing and selected developed economies. The precise context of the research considers/compares the impact and potential/possible relationships of meaningfully selected macroeconomic variables, upon respective stock market indices of two sets of economies - BRICS (i.e. Brazil, Russia, India, China and South Africa) and five meaningfully selected developed economies (i.e. France, Germany, Japan, UK and US). Thus, a significant motivation for the research is to evaluate/test theoretical linkages and empirical relationships of selected macroeconomic variables, in terms of their predictive power vis a vis related stock market indices. The research then offers consequent policy implications/contributions. It is of benefit and significance to (inter alia) investors, who would welcome "early signals" when evaluating stock markets via relevant indices. In so doing, the research adds theoretical and empirical knowledge, with practical potential, to this domain. Finally, within its concluding chapter, the thesis also offers some suggestions for further research and future researchers. Against the above background, the research addresses ten individual, but related, objectives (Chapter II). These objectives range from an attempt to identify the directional and potentially causal relationship between sets of selected macroeconomic variables and relevant stock market indices (Objective 3), through to determining dynamic relationships across sets of comparable indices (Objective 10). The literature review (Chapter III) confirms the relative absence of relevant empirical literature within developing countries. However, related literature within developed economies does prevail. For instance, in terms of the U.S., Domian and Louton (1997) find evidence that stock price declines (and so of market indices) are associated with abrupt decreases in growth rates of industrial production and increases are comparably associated with mild increases in industrial production. Equally, in terms of Germany, France, United Kingdom, Sweden, Japan, Canada and United States, Longin and Solnik (1995) provide evidence in terms of the predictive power of macroeconomic variables related to stock prices (and by implication indices). Accordingly, the extant research literature reveals a gap. There appears to be no study that comparatively analyses the effects of the 2007-8 financial crisis between the BRICS and the five developed countries, selected for this analysis. Equally, in contrast to the present research, there appears to be no study that (as "dummy" variables) tests the effect of the US quantitative easing policy undertaken during the financial crisis, on the financial markets of BRICS and the five selected developed countries. And, therein lies some of the uniqueness and original contribution of this research. Saunders et al. (2016) who consider the construction of research with the six "layers" of their "Research Onion" influence the research design and methodology (Chapter IV). Thus, with explanations provided within the thesis, the research engages with five of these "layers" as follows: philosophy - positivist, approach - deductive, strategy - archival, choice of method - quantitative - but with qualitative elements. The research time-horizon is longitudinal, with, respectively, the same dependent (identified stock market indices) and independent (selected macroeconomic variables) research variables being considered and analysed over a significant period of time (January 2000 to December 2015). Thus, the research data are mainly stock market indices (dependent variables) and meaningfully identified macroeconomic features (independent variables - derived from a Keran diagram), over the research period. Equally, appropriately developed variables, intended to quantitatively capture the 2008 financial crisis and the US quantitative easing are also used as dummy variables within the independent variable data set. The research data itself and its analysis, and the dependent and independent variables are identified and rationalised within the thesis. And, in this context, the research draws on, and analyses, pre-existing quantitative data stored (mainly) in the Bloomberg repository - a public database. This public accessibility obviates ethical issues relating to the access, use and storage of the research data. The research mathematical/statistical procedures and analyses (Chapter V), mainly computed descriptive and inferential statistics, are developed and presented within the research, Firstly, in order to condition and/or quality control variables, appropriate pre-statistical operations (including Units Roots Tests, Correlations, Seasonal Adjustments and Log Transformations) are duly performed on quantitative data. Then, descriptive statistics (including mean, mode, median and standard deviation) are developed (primarily) in order to reveal and describe properties of the variables attached to the cases, and to be assured that the inferential statistical tests to be applied to them are, indeed, appropriate. Finally, appropriate inferential statistics are applied and determined as necessitated by individual and particular research objectives.
- Published
- 2018
- Full Text
- View/download PDF
33. Service innovations: development of a psychoeducational programme for patients with personality disorder
- Author
-
D'Silva, K.
- Published
- 2002
- Full Text
- View/download PDF
34. Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
- Author
-
Su-Ann Yeoh, Milena Gianfrancesco, Saskia Lawson-Tovey, Kimme L Hyrich, Anja Strangfeld, Laure Gossec, Loreto Carmona, Elsa F Mateus, Martin Schäfer, Christophe Richez, Eric Hachulla, Marie Holmqvist, Carlo Alberto Scirè, Hanns-Martin Lorenz, Reinhard E Voll, Rebecca Hasseli, Arundathi Jayatilleke, Tiffany Y-T Hsu, Kristin M D’Silva, Victor R Pimentel-Quiroz, Monica Vasquez del Mercado, Samuel Katsuyuki Shinjo, Edgard Torres dos Reis Neto, Laurindo Ferreira da Rocha Junior, Ana Carolina de Oliveira e Silva Montandon, Guillermo J Pons-Estel, Sofía Ornella, Maria Eugenia D'Angelo Exeni, Edson Velozo, Paula Jordan, Emily Sirotich, Jonathan S Hausmann, Jean W Liew, Lindsay Jacobsohn, Monique Gore-Massy, Paul Sufka, Rebecca Grainger, Suleman Bhana, Zachary Wallace, Philip C Robinson, Jinoos Yazdany, Pedro M Machado, Yeoh, S, Gianfrancesco, M, Lawson-Tovey, S, Hyrich, K, Strangfeld, A, Gossec, L, Carmona, L, Mateus, E, Schafer, M, Richez, C, Hachulla, E, Holmqvist, M, Scire, C, Lorenz, H, Voll, R, Hasseli, R, Jayatilleke, A, Hsu, T, D'Silva, K, Pimentel-Quiroz, V, Vasquez Del Mercado, M, Shinjo, S, Neto, E, Junior, L, De Oliveira E Silva Montandon, A, Pons-Estel, G, Ornella, S, D'Angelo Exeni, M, Velozo, E, Jordan, P, Sirotich, E, Hausmann, J, Liew, J, Jacobsohn, L, Gore-Massy, M, Sufka, P, Grainger, R, Bhana, S, Wallace, Z, Robinson, P, Yazdany, J, and Machado, P
- Subjects
Adult ,Male ,Myositis ,dermatomyositis ,polymyositi ,Prednisolone ,Immunology ,outcome assessment, health care ,COVID-19 ,polymyositis ,COVID-19 Testing ,Rheumatology ,Physicians ,Humans ,Immunology and Allergy ,Female ,dermatomyositi ,epidemiology ,Registries ,Rituximab - Abstract
ObjectivesTo investigate factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy (IIM).MethodsDemographic data, clinical characteristics and COVID-19 outcome severity of adults with IIM were obtained from the COVID-19 Global Rheumatology Alliance physician-reported registry. A 3-point ordinal COVID-19 severity scale was defined: (1) no hospitalisation, (2) hospitalisation (and no death) and (3) death. ORs were estimated using multivariable ordinal logistic regression. Sensitivity analyses were performed using a 4-point ordinal scale: (1) no hospitalisation, (2) hospitalisation with no oxygen (and no death), (3) hospitalisation with oxygen/ventilation (and no death) and 4) death.ResultsOf 348 patients, 48% were not hospitalised, 39% were hospitalised (and did not die) and 13% died. Older age (OR=1.59/decade, 95% CI 1.31 to 1.91), high disease activity (OR=3.50, 95% CI 1.25 to 9.83; vs remission), ≥2 comorbidities (OR=2.63, 95% CI 1.39 to 4.98; vs none), prednisolone-equivalent dose >7.5 mg/day (OR=2.40, 95% CI 1.09 to 5.28; vs no intake) and exposure to rituximab (OR=2.71, 95% CI 1.28 to 5.72; vs conventional synthetic disease-modifying antirheumatic drugs only) were independently associated with severe COVID-19. In addition to these variables, in the sensitivity analyses, male sex (OR range: 1.65–1.83; vs female) was also significantly associated with severe outcomes, while COVID-19 diagnosis after 1 October 2020 (OR range: 0.51–0.59; vs on/before 15 June 2020) was significantly associated with less severe outcomes, but these associations were not significant in the main model (OR=1.57, 95% CI 0.95 to 2.59; and OR=0.61, 95% CI 0.37 to 1.00; respectively).ConclusionsThis is the first large registry data on outcomes of COVID-19 in people with IIM. Older age, male sex, higher comorbidity burden, high disease activity, prednisolone-equivalent dose >7.5 mg/day and rituximab exposure were associated with severe COVID-19. These findings will enable risk stratification and inform management decisions for patients with IIM.
- Published
- 2022
- Full Text
- View/download PDF
35. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
- Author
-
Maria Margarida Cunha, Gabriela Schmajuk, Rebecca Hasseli, Namrata Singh, Tiffany Y.T. Hsu, Milena A. Gianfrancesco, Anja Strangfeld, Ranjeny Thomas, Naomi J Patel, Thierry Thomas, Philippe Dieudé, Kimme L. Hyrich, Emily Sirotich, Laura Trupin, Liselotte Tidblad, Jinoos Yazdany, René Marc Flipo, Licia Maria Henrique da Mota, Andrea M Seet, Samar Al Emadi, Carolina A. Isnardi, Saskia Lawson-Tovey, Alí Duarte-García, Hendrik Schulze-Koops, Manuel F. Ugarte-Gil, Vanessa L. Kronzer, Philip Robinson, Lindsay Jacobsohn, Elsa F Mateus, Pedro Machado, Ana Paula Monteiro Gomides, Jean W. Liew, Guillermo A. Berbotto, Miguel Bernardes, Patricia P. Katz, Martin Schäfer, Guillermo J. Pons-Estel, Ulf Müller-Ladner, Jeffrey A. Sparks, Elena Nikiphorou, Christof Specker, Paul Sufka, Zara Izadi, Loreto Carmona, Stephanie Rush, Sandra Lúcia Euzébio Ribeiro, Maria O Valenzuela-Almada, Kristin M. D’Silva, Emily L Gilbert, Raphaèle Seror, Laure Gossec, Beth I Wallace, Viviane Angelina de Souza, Akpabio Akpabio, Jérôme Avouac, Leanna Wise, Wendy Costello, Zachary S. Wallace, Suleman Bhana, Jonathan S. Hausmann, Lianne Kearsley-Fleet, Bernd Raffeiner, Carlo Alberto Scirè, Rebecca Grainger, Sparks, J, Wallace, Z, Seet, A, Gianfrancesco, M, Izadi, Z, Hyrich, K, Strangfeld, A, Gossec, L, Carmona, L, Mateus, E, Lawson-Tovey, S, Trupin, L, Rush, S, Katz, P, Schmajuk, G, Jacobsohn, L, Wise, L, Gilbert, E, Duarte-Garcia, A, Valenzuela-Almada, M, Pons-Estel, G, Isnardi, C, Berbotto, G, Hsu, T, D'Silva, K, Patel, N, Kearsley-Fleet, L, Schafer, M, Ribeiro, S, Al Emadi, S, Tidblad, L, Scire, C, Raffeiner, B, Thomas, T, Flipo, R, Avouac, J, Seror, R, Bernardes, M, Cunha, M, Hasseli, R, Schulze-Koops, H, Muller-Ladner, U, Specker, C, De Souza, V, Da Mota, L, Gomides, A, Dieude, P, Nikiphorou, E, Kronzer, V, Singh, N, Ugarte-Gil, M, Wallace, B, Akpabio, A, Thomas, R, Bhana, S, Costello, W, Grainger, R, Hausmann, J, Liew, J, Sirotich, E, Sufka, P, Robinson, P, Machado, P, and Yazdany, J
- Subjects
Male ,medicine.medical_specialty ,abatacept ,Coronavirus disease 2019 (COVID-19) ,Immunology ,tumour necrosis factor inhibitors ,tumour necrosis factor inhibitor ,Antirheumatic Agents/therapeutic use ,Rheumatoid Arthritis ,Severity of Illness Index ,General Biochemistry, Genetics and Molecular Biology ,Arthritis, Rheumatoid ,03 medical and health sciences ,0302 clinical medicine ,rituximab ,Rheumatology ,Arthritis, Rheumatoid/complications ,Internal medicine ,medicine ,Immunology and Allergy ,Humans ,030212 general & internal medicine ,Registries ,Interleukin 6 ,Aged ,030203 arthritis & rheumatology ,biology ,business.industry ,SARS-CoV-2 ,Abatacept ,Confounding ,COVID-19 ,rheumatoid arthriti ,Middle Aged ,medicine.disease ,Drug class ,Rheumatoid arthritis ,Antirheumatic Agents ,COVID-19/complications ,biology.protein ,Rituximab ,Female ,business ,medicine.drug - Abstract
ObjectiveTo investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA).MethodsWe analysed the COVID-19 Global Rheumatology Alliance physician registry (from 24 March 2020 to 12 April 2021). We investigated b/tsDMARD use for RA at the clinical onset of COVID-19 (baseline): abatacept (ABA), rituximab (RTX), Janus kinase inhibitors (JAKi), interleukin 6 inhibitors (IL-6i) or tumour necrosis factor inhibitors (TNFi, reference group). The ordinal COVID-19 severity outcome was (1) no hospitalisation, (2) hospitalisation without oxygen, (3) hospitalisation with oxygen/ventilation or (4) death. We used ordinal logistic regression to estimate the OR (odds of being one level higher on the ordinal outcome) for each drug class compared with TNFi, adjusting for potential baseline confounders.ResultsOf 2869 people with RA (mean age 56.7 years, 80.8% female) on b/tsDMARD at the onset of COVID-19, there were 237 on ABA, 364 on RTX, 317 on IL-6i, 563 on JAKi and 1388 on TNFi. Overall, 613 (21%) were hospitalised and 157 (5.5%) died. RTX (OR 4.15, 95% CI 3.16 to 5.44) and JAKi (OR 2.06, 95% CI 1.60 to 2.65) were each associated with worse COVID-19 severity compared with TNFi. There were no associations between ABA or IL6i and COVID-19 severity.ConclusionsPeople with RA treated with RTX or JAKi had worse COVID-19 severity than those on TNFi. The strong association of RTX and JAKi use with poor COVID-19 outcomes highlights prioritisation of risk mitigation strategies for these people.
- Published
- 2021
- Full Text
- View/download PDF
36. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19
- Author
-
Ryan C. Ungaro, Therapy Psoriasis Patient Registry for Outcomes, Leanna Wise, Hanns-Martin Lorenz, Pascal Claudepierre, Suleman Bhana, Michael D. Kappelman, Anja Strangfeld, Loreto Carmona, Wendy Costello, Eva Klingberg, Elsa F Mateus, Pedro Machado, Rosana Quintana, Jeffrey A. Sparks, Mark Yates, Zara Izadi, Erica J. Brenner, Nick Dand, Jean W. Liew, Bimba F. Hoyer, Gabriela Schmajuk, Alí Duarte-García, Carolina A. Isnardi, Saskia Lawson-Tovey, Kristin M. D’Silva, Patricia P. Katz, Manasi Agrawal, Jinoos Yazdany, Philippe Goupille, Zenas Z N Yiu, Zachary S. Wallace, Enrique R. Soriano, Catherine H. Smith, Ana Rita Cruz-Machado, Emily L Gilbert, Naomi J Patel, Maria O Valenzuela-Almada, Jonathan S. Hausmann, Christopher E.M. Griffiths, Giovanna Cuomo, Emily Sirotich, Stephanie Rush, Laura Trupin, Ana Carolina Mazeda Pereira, Xian Zhang, Kimme L. Hyrich, Jean-Frederic Colombel, René-Marc Flipo, Rebecca Hasseli, Alain Cantagrel, Satveer K. Mahil, Marta Caprioli, Andrea M Seet, Samar Al Emadi, Philip Robinson, Claudia Diniz Lopes Marques, Ricardo Machado Xavier, Rebecca Grainger, Tiffany Y-T Hsu, Lindsay Jacobsohn, Adriana Maria Kakehasi, Paul Sufka, Milena A. Gianfrancesco, Alexander Pfeil, Jonathan Barker, Izadi, Z., Brenner, E. J., Mahil, S. K., Dand, N., Yiu, Z. Z. N., Yates, M., Ungaro, R. C., Zhang, X., Agrawal, M., Colombel, J. -F., Gianfrancesco, M. A., Hyrich, K. L., Strangfeld, A., Carmona, L., Mateus, E. F., Lawson-Tovey, S., Klingberg, E., Cuomo, G., Caprioli, M., Cruz-Machado, A. R., Mazeda Pereira, A. C., Hasseli, R., Pfeil, A., Lorenz, H. -M., Hoyer, B. F., Trupin, L., Rush, S., Katz, P., Schmajuk, G., Jacobsohn, L., Seet, A. M., Al Emadi, S., Wise, L., Gilbert, E. L., Duarte-Garcia, A., Valenzuela-Almada, M. O., Isnardi, C. A., Quintana, R., Soriano, E. R., Hsu, T. Y. -T., D'Silva, K. M., Sparks, J. A., Patel, N. J., Xavier, R. M., Marques, C. D. L., Kakehasi, A. M., Flipo, R. -M., Claudepierre, P., Cantagrel, A., Goupille, P., Wallace, Z. S., Bhana, S., Costello, W., Grainger, R., Hausmann, J. S., Liew, J. W., Sirotich, E., Sufka, P., Robinson, P. C., Machado, P. M., Griffiths, C. E. M., Barker, J. N., Smith, C. H., Yazdany, J., Kappelman, M. D., APH - Methodology, APH - Quality of Care, AII - Inflammatory diseases, and Dermatology
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Azathioprine ,Comorbidity ,Lower risk ,Inflammatory bowel disease ,Arthritis, Rheumatoid ,Internal medicine ,Psoriasis ,medicine ,Humans ,Registries ,Pandemics ,Retrospective Studies ,Original Investigation ,SARS-CoV-2 ,Tumor Necrosis Factor-alpha ,business.industry ,Research ,COVID-19 ,Retrospective cohort study ,General Medicine ,Odds ratio ,Middle Aged ,Inflammatory Bowel Diseases ,medicine.disease ,TNF inhibitor ,Hospitalization ,Online Only ,Infectious Diseases ,Rheumatoid arthritis ,Drug Therapy, Combination ,Female ,Tumor Necrosis Factor Inhibitors ,business ,medicine.drug - Abstract
Key Points Question Is receipt of tumor necrosis factor (TNF) inhibitor monotherapy at the time of COVID-19 diagnosis associated with adverse COVID-19 outcomes compared with other treatment regimens among patients with immune-mediated inflammatory diseases (IMIDs)? Findings In this cohort study of 6077 patients with IMIDs and COVID-19, TNF inhibitors in combination with azathioprine/6-mercaptopurine therapy, methotrexate monotherapy, azathioprine/6-mercaptopurine monotherapy, or Janus kinase inhibitor monotherapy were each associated with significantly higher odds of hospitalization or death compared with TNF inhibitor monotherapy. Meaning This study’s findings support the continued use of TNF inhibitor monotherapy among individuals with IMIDs during the pandemic., Importance Although tumor necrosis factor (TNF) inhibitors are widely prescribed globally because of their ability to ameliorate shared immune pathways across immune-mediated inflammatory diseases (IMIDs), the impact of COVID-19 among individuals with IMIDs who are receiving TNF inhibitors remains insufficiently understood. Objective To examine the association between the receipt of TNF inhibitor monotherapy and the risk of COVID-19–associated hospitalization or death compared with other commonly prescribed immunomodulatory treatment regimens among adult patients with IMIDs. Design, Setting, and Participants This cohort study was a pooled analysis of data from 3 international COVID-19 registries comprising individuals with rheumatic diseases, inflammatory bowel disease, and psoriasis from March 12, 2020, to February 1, 2021. Clinicians directly reported COVID-19 outcomes as well as demographic and clinical characteristics of individuals with IMIDs and confirmed or suspected COVID-19 using online data entry portals. Adults (age ≥18 years) with a diagnosis of inflammatory arthritis, inflammatory bowel disease, or psoriasis were included. Exposures Treatment exposure categories included TNF inhibitor monotherapy (reference treatment), TNF inhibitors in combination with methotrexate therapy, TNF inhibitors in combination with azathioprine/6-mercaptopurine therapy, methotrexate monotherapy, azathioprine/6-mercaptopurine monotherapy, and Janus kinase (Jak) inhibitor monotherapy. Main Outcomes and Measures The main outcome was COVID-19–associated hospitalization or death. Registry-level analyses and a pooled analysis of data across the 3 registries were conducted using multilevel multivariable logistic regression models, adjusting for demographic and clinical characteristics and accounting for country, calendar month, and registry-level correlations. Results A total of 6077 patients from 74 countries were included in the analyses; of those, 3215 individuals (52.9%) were from Europe, 3563 individuals (58.6%) were female, and the mean (SD) age was 48.8 (16.5) years. The most common IMID diagnoses were rheumatoid arthritis (2146 patients [35.3%]) and Crohn disease (1537 patients [25.3%]). A total of 1297 patients (21.3%) were hospitalized, and 189 patients (3.1%) died. In the pooled analysis, compared with patients who received TNF inhibitor monotherapy, higher odds of hospitalization or death were observed among those who received a TNF inhibitor in combination with azathioprine/6-mercaptopurine therapy (odds ratio [OR], 1.74; 95% CI, 1.17-2.58; P = .006), azathioprine/6-mercaptopurine monotherapy (OR, 1.84; 95% CI, 1.30-2.61; P = .001), methotrexate monotherapy (OR, 2.00; 95% CI, 1.57-2.56; P, This cohort study uses data from 3 international registries to examine the association between the receipt of tumor necrosis factor monotherapy and the risk of COVID-19–associated hospitalization or death among adult patients with immune-mediated inflammatory diseases.
- Published
- 2021
- Full Text
- View/download PDF
37. Predicting the temporal activity patterns of new venues
- Author
-
D'Silva, Krittika, Noulas, Anastasios, Musolesi, Mirco, Mascolo, Cecilia, Sklar, Max, D'Silva, K and Noulas, A and Musolesi, M and Mascolo, C and Sklar, M, Apollo - University of Cambridge Repository, D'Silva, Krittika [0000-0002-1411-8523], and Mascolo, Cecilia [0000-0001-9614-4380]
- Subjects
Social and Information Networks (cs.SI) ,FOS: Computer and information sciences ,Online social media analysis, data mining, mobility prediction ,Urban computing ,Spatio-temporal patterns ,lcsh:R858-859.7 ,Human mobility prediction ,Computer Science - Social and Information Networks ,Regular Article ,lcsh:Computer applications to medicine. Medical informatics ,Urban traffic - Abstract
Estimating revenue and business demand of a newly opened venue is paramount as these early stages often involve critical decisions such as first rounds of staffing and resource allocation. Traditionally, this estimation has been performed through coarse-grained measures such as observing numbers in local venues or venues at similar places (e.g., coffee shops around another station in the same city). The advent of crowdsourced data from devices and services carried by individuals on a daily basis has opened up the possibility of performing better predictions of temporal visitation patterns for locations and venues. In this paper, using mobility data from Foursquare, a location-centric platform, we treat venue categories as proxies for urban activities and analyze how they become popular over time. The main contribution of this work is a prediction framework able to use characteristic temporal signatures of places together with k-nearest neighbor metrics capturing similarities among urban regions, to forecast weekly popularity dynamics of a new venue establishment in a city neighborhood. We further show how we are able to forecast the popularity of the new venue after one month following its opening by using locality and temporal similarity as features. For the evaluation of our approach we focus on London. We show that temporally similar areas of the city can be successfully used as inputs of predictions of the visit patterns of new venues, with an improvement of 41% compared to a random selection of wards as a training set for the prediction task. We apply these concepts of temporally similar areas and locality to the real-time predictions related to new venues and show that these features can effectively be used to predict the future trends of a venue. Our findings have the potential to impact the design of location-based technologies and decisions made by new business owners., Foursquare
- Published
- 2018
- Full Text
- View/download PDF
38. If I build it, will they come?
- Author
-
Anastasios Noulas, Cecilia Mascolo, Mirco Musolesi, Krittika D'Silva, Max Sklar, Hoel, EG and Newsam, SD and Ravada, S and Tamassia, R and Trajcevski, G, D'Silva, K, Noulas, A, Musolesi, M, Mascolo, C, and Sklar, M
- Subjects
Estimation ,Computer science ,media_common.quotation_subject ,0211 other engineering and technologies ,Staffing ,020206 networking & telecommunications ,021107 urban & regional planning ,02 engineering and technology ,Data science ,Popularity ,Online social networks, data analytics ,Work (electrical) ,Service (economics) ,Urban computing ,0202 electrical engineering, electronic engineering, information engineering ,Resource allocation ,Revenue ,media_common - Abstract
Estimating revenue and business demand of a newly opened venue is paramount as these early stages often involve critical decisions such as first rounds of staffing and resource allocation. Traditionally, this estimation has been performed through coarse measures such as observing numbers in local venues. The advent of crowdsourced data from devices and services has opened the door to better predictions of temporal visitation patterns for locations and venues. In this paper, using mobility data from the location-based service Foursquare, we treat venue categories as proxies for urban activities and analyze how they become popular over time. The main contribution of this work is a prediction framework able to use characteristic temporal signatures of places together with k-nearest neighbor metrics capturing similarities among urban regions to forecast weekly popularity dynamics of a new venue establishment. Our evaluation shows that temporally similar areas of a city can be valuable predictors, decreasing error by 41%. Our findings have the potential to impact the design of location-based technologies and decisions made by new business owners.
- Published
- 2017
- Full Text
- View/download PDF
39. Upadacitinib in Active Non-radiographic Axial Spondyloarthritis: 1-Year Data From a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial.
- Author
-
Van den Bosch F, Deodhar A, Poddubnyy D, Maksymowych WP, van der Heijde D, Kim TH, Kishimoto M, Baraliakos X, Li Y, D'Silva K, Wung P, and Song IH
- Abstract
Objective: Upadacitinib improved the signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) versus placebo over 14 weeks in the primary analysis of the SELECT-AXIS 2 nr-axSpA study. Here, we evaluated the efficacy and safety of upadacitinib through 1 year in patients with nr-axSpA in SELECT-AXIS 2., Methods: Patients aged at least 18 years diagnosed with nr-axSpA who fulfilled the 2009 Assessment of SpondyloArthritis International Society (ASAS) classification criteria and were receiving stable background therapy were randomized to upadacitinib 15 mg once daily or placebo for the 52-week double-blind period. Efficacy was assessed using non-responder imputation incorporating multiple imputation (NRI-MI) and as-observed analyses for binary endpoints, and mixed-effects model repeated measures for continuous endpoints., Results: Of 314 randomized patients, 259 (upadacitinib, n = 129; placebo, n = 130) completed 52 weeks of treatment. More patients receiving upadacitinib versus placebo achieved ≥40% improvement in ASAS at week 52 (63% vs 43%, NRI-MI; nominal P < 0.001). Similar treatment effects were observed for the achievement of axSpA Disease Activity Score inactive disease (33% v 11%, NRI-MI; nominal P < 0.001). Overall, patients receiving upadacitinib versus placebo showed greater improvement in disease activity, inflammation, pain, function, enthesitis, and quality of life through 52 weeks. Adverse events were generally comparable between the treatment groups. No opportunistic infections, malignancies, major adverse cardiovascular events, venous thromboembolic events, inflammatory bowel disease, or deaths were reported in those receiving upadacitinib., Conclusion: Treatment with upadacitinib showed sustained efficacy versus placebo with no new safety findings identified through 1 year. These results support the continued favorable benefit-risk profile of upadacitinib treatment for nr-axSpA., (© 2024 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.)
- Published
- 2024
- Full Text
- View/download PDF
40. Catastrophic Thrombotic Storm.
- Author
-
Rodriguez JA, D'Silva K, Kohler M, Ghoshhajra B, and Hedgire S
- Subjects
- Humans, Antiphospholipid Syndrome complications, Thrombosis diagnostic imaging
- Published
- 2021
- Full Text
- View/download PDF
41. Renal deposits of complement factors as predictors of end-stage renal disease and death in patients with lupus nephritis.
- Author
-
Koopman JJE, Rennke HG, Leatherwood C, Speyer CB, D'Silva K, McMahon GM, Waikar SS, and Costenbader KH
- Subjects
- Adult, Boston epidemiology, Female, Humans, Kidney Failure, Chronic immunology, Lupus Nephritis complications, Lupus Nephritis mortality, Male, Middle Aged, Retrospective Studies, Complement C1q metabolism, Complement C3 metabolism, Kidney metabolism, Kidney Failure, Chronic metabolism, Lupus Nephritis metabolism
- Abstract
Objective: Lupus nephritis (LN) increases the risks of end-stage renal disease (ESRD) and death, but these risks are difficult to estimate. Since complement factors play an essential role in the pathogenesis and are deposited in the kidneys as C1q and C3, we studied whether these deposits predict ESRD and death in patients with LN., Methods: We collected demographic, clinical and pathological data from 183 adult patients with LN classes II-V diagnosed with a first native kidney biopsy. Pathological data included the localization and intensity of immunofluorescence staining of C1q and C3. We obtained dates of incident ESRD and death from the United States Renal Data System and National Death Index, respectively, and evaluated survival curves and hazard ratios for ESRD and death as a composite outcome and as separate outcomes., Results: The presence and intensity of deposits of C1q and C3 in glomeruli, tubular walls and vascular walls differed between classes and were associated with known unfavourable prognostic factors, such as hypertension, hypoalbuminemia and hypocomplementemia. However, over a median follow-up of 7.5 years, their presence and intensity were associated with neither survival free of ESRD and death nor hazard ratios for ESRD and death., Conclusion: Renal deposits of complement factors did not predict ESRD and death in patients with LN., (© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology.)
- Published
- 2020
- Full Text
- View/download PDF
42. Using electronic visits (E-visits) to achieve goal serum urate levels in patients with gout in a rheumatology practice: A pilot study.
- Author
-
Yokose C, Jorge A, D'Silva K, Serling-Boyd N, Matza M, Nasrallah M, Keller S, Oza A, Choi H, Bolster MB, and Collier D
- Subjects
- Electronics, Goals, Gout Suppressants therapeutic use, Humans, Pilot Projects, Retrospective Studies, Treatment Outcome, Uric Acid, Gout drug therapy, Rheumatology
- Abstract
Objective: Achieving goal serum urate levels in patients with gout remains difficult in primary care and rheumatology practices. This study measured the ability of an asynchronous electronic visit (E-visit) program to facilitate achieving a goal serum urate (SU) of less than 6.0 mg/dL., Methods: We performed a retrospective cohort study in a large academic medical center rheumatology practice between April 1, 2017 and May 31, 2018. Patients with gout and SU levels over 6.0 mg/dL were enrolled in an E-visit program and were compared with historical controls who received usual care, matched 1:1 for age and sex. The primary outcome of interest was the proportion of patients achieving SU target of less than 6.0 mg/dL at six months., Results: Sixty-two patients were enrolled by their rheumatologist in the gout asynchronous E-visit program and were compared to 62 historical controls who were seen within one year prior to E-visit program initiation. Baseline characteristics including age, sex, body mass index, renal function, and initial SU were similar among patients enrolled in the E-visit program and controls. At six months, a significantly higher proportion of patients in the E-visit program achieved goal SU of less than 6.0 mg/dL compared to controls (63.8% vs 33.9%, respectively, p < 0.01), and the E-visit patients had a lower mean SU level than historical controls (5.5 mg/dL versus 6.7 mg/dL, respectively, p < 0.01)., Conclusion: A physician-initiated E-visit program led to a substantial improvement in the rate of achieving goal SU among patients with gout within an academic rheumatology practice., Competing Interests: Declaration of Competing Interest No authors report conflicts of interest., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
43. Identification of additives in polymers from single-use bioprocessing bags by accelerated solvent extraction and ultra-high performance liquid chromatography coupled with high-resolution mass spectrometry.
- Author
-
Dorival-García N, Galbiati F, Kruell R, Kovasy R, Dunne SO, D'Silva K, and Bones J
- Subjects
- Chromatography, High Pressure Liquid, Chromatography, Liquid, Mass Spectrometry, Solvents, Polymers
- Abstract
Single-use technologies are increasingly used in biopharmaceutical manufacturing. Despite their advantages, these plastic assemblies draw concern because they are a potential source of contamination due to extractable and leachable compounds (E&Ls). Characterising E&Ls from such materials is a necessary step in establishing their suitability for use. Therefore, there is an urgent need for sensitive methods to identify and quantitatively assess compounds in plastic materials. Accelerated solvent extraction (ASE) is a powerful technique that can be reliably used for this purpose. In this study, ASE followed by liquid chromatography and Orbitrap-based High Resolution Accurate Mass (HRAM) mass analysis was found to be an efficient and versatile method for the determination of additives in different multilayer polymer systems from single-use bags. ASE optimisation was performed using a design of experiments approach. The type of solvent, temperature, swelling agent addition, static time and number of cycles were the selected variables. Optimum conditions were dependent on the type of plastic film. Ethyl acetate and cyclohexane were selected individually as optimum solvents. Optimum temperatures were 90-100 °C. Pressure was set at 1500 psi and extraction time was 30 min in 2 cycles. Swelling agent addition was necessary with polar extraction solvents. More than 100 additives and degradation products were confidently identified by HRAM MS. Correlations between the type and levels of identified additives and the type of polymer system were established. In addition, degradation behaviour and pathways for some additives can be addressed., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
44. A Rapid Change in Pressure.
- Author
-
D'Silva K, Cockrill B, Anderson WJ, Miller AL, and Loscalzo J
- Subjects
- Adenocarcinoma complications, Adenocarcinoma secondary, Aged, Computed Tomography Angiography, Diagnosis, Differential, Echocardiography, Fatal Outcome, Female, Heart Failure diagnostic imaging, Heart Failure etiology, Humans, Hypertension, Pulmonary diagnosis, Lung diagnostic imaging, Lung Neoplasms complications, Positron Emission Tomography Computed Tomography, Thrombotic Microangiopathies, Adenocarcinoma diagnosis, Dyspnea etiology, Hypertension, Pulmonary etiology, Lung pathology, Lung Neoplasms diagnosis
- Published
- 2020
- Full Text
- View/download PDF
45. Clinical characteristics and renal prognosis associated with interstitial fibrosis and tubular atrophy (IFTA) and vascular injury in lupus nephritis biopsies.
- Author
-
Leatherwood C, Speyer CB, Feldman CH, D'Silva K, Gómez-Puerta JA, Hoover PJ, Waikar SS, McMahon GM, Rennke HG, and Costenbader KH
- Subjects
- Adult, Atrophy pathology, Disease Progression, Female, Fibrosis pathology, Humans, Male, Retrospective Studies, Risk Factors, Biopsy methods, Kidney Tubules pathology, Lupus Nephritis pathology, Renal Artery pathology
- Abstract
Background: Interstitial fibrosis and tubular atrophy (IFTA) and vascular injury are frequent histologic features of lupus nephritis renal biopsies, but their clinical correlates and prognostic value are not well understood. This cohort study investigated demographic, clinical and laboratory characteristics, and outcomes, associated with IFTA and vascular injury in lupus nephritis., Methods: Reports of all renal biopsies performed at an academic medical center (1990-2017) with WHO/ISN/RPS Class II-V lupus nephritis were reviewed. Demographics, clinical variables and labs at biopsy, treatment, and date of death were collected. Additional data from the U.S. Renal Data System (USRDS) provided dates of ESRD and death after ESRD. Multivariable regression analyses identified demographic and clinical factors associated with each histologic finding. Cumulative incidence functions and multivariable Cox proportional hazard models estimated the risk of progression to ESRD and death., Results: Within 202 initial biopsies, IFTA was associated with the patient's SLICC/ACR damage index (without renal domain) and serum creatinine, and vascular injury was associated with serum creatinine in multivariable models. In Cox regression models adjusting for age, sex, race, serum creatinine, calendar year, and biopsy class, moderate/severe IFTA was associated with elevated ESRD (HR
SD 5.18, 95% CI 2.53, 10.59) and death (HR 4.19, 95%CI 1.27, 13.81). After adjustment for age, sex and race, moderate/severe vascular injury was associated with ESRD (HRSD 2.13, 95% CI 1.21, 3.75) and but this relationship was not significant after adjustment for serum creatinine and calendar year., Conclusions: IFTA is a strong predictor of ESRD and death, even in proliferative nephritis, and a risk factor for poor outcomes independent of class. Vascular injury is a strong predictor of prognosis, but not independent of serum creatinine and class. The prognostic value of these lesions calls for consideration when determining treatment for lupus nephritis., (Copyright © 2019 Elsevier Inc. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
46. Gasping for a Diagnosis.
- Author
-
D'Silva K, Brown S, Hunninghake GM, Vivero M, and Loscalzo J
- Subjects
- Adult, Biopsy, Bronchoalveolar Lavage, Bronchoscopy, Cough etiology, Diagnosis, Differential, Granulocyte-Macrophage Colony-Stimulating Factor therapeutic use, Humans, Hypoxia etiology, Lung diagnostic imaging, Male, Pneumonia diagnosis, Pulmonary Alveolar Proteinosis complications, Pulmonary Alveolar Proteinosis therapy, Tomography, X-Ray Computed, Dyspnea etiology, Lung pathology, Pulmonary Alveolar Proteinosis diagnosis
- Published
- 2019
- Full Text
- View/download PDF
47. Large-Scale Assessment of Extractables and Leachables in Single-Use Bags for Biomanufacturing.
- Author
-
Dorival-García N, Carillo S, Ta C, Roberts D, Comstock K, Lofthouse S, Ciceri E, D'Silva K, Kierans G, Kaisermayer C, Lindeberg A, and Bones J
- Subjects
- Biological Products chemistry, Chromatography, Liquid instrumentation, Chromatography, Liquid methods, Drug Packaging instrumentation, Equipment Design, Gas Chromatography-Mass Spectrometry instrumentation, Gas Chromatography-Mass Spectrometry methods, Humans, Liquid Phase Microextraction instrumentation, Liquid Phase Microextraction methods, Mass Spectrometry instrumentation, Tandem Mass Spectrometry instrumentation, Tandem Mass Spectrometry methods, Drug Contamination prevention & control, Drug Packaging methods, Mass Spectrometry methods, Plastics analysis, Solvents analysis, Volatile Organic Compounds analysis
- Abstract
Single-use technologies (SUTs) are widely used during biopharmaceutical manufacture as disposable bioreactors or media and buffer storage bags. Despite their advantages, the risk of release of extractable and leachable (E&Ls) substances is considered an important drawback in adopting disposables in the biomanufacturing process. E&Ls may detrimentally affect cell viability or productivity or may persist during purification and present a risk to the patient if remaining in the final drug product. In this study, 34 plastic films from single-use bags (SUBs) for cell cultivation were extracted with selected solvents that represent reasonable worst-case conditions for most typical biomanufacturing applications. SUBs were incubated at small-scale under accelerated-aging conditions that represented standard operational conditions of use. Leachables analysis was performed following dispersive liquid-liquid microextraction (DLLME) for analyte preconcentration and removal of matrix interference. Resulting extracts were characterized by GC-headspace for volatiles, high resolution GC-Orbitrap-MS/MS for semivolatiles, high resolution LC-Orbitrap-MS/MS for nonvolatiles, and ICP-MS for trace elemental analysis. Multivariate statistical analysis of the analytical data revealed significant correlations between the type and concentration of compounds and bags features including brand, manufacturing date and polymer type. The analytical data demonstrates that, over recent years, the nature of E&Ls has been altered due to the implementation of manufacturing changes and new types of polymers and may change further with the future advent of regulations that will limit or ban the use of certain raw materials and additives. The broad E&L database generated herein facilitates toxicological assessments from a biomanufacturing standpoint and provides practical guidelines for confident determination of E&Ls to enable screening and elimination of nonsatisfactory films for single use bioprocessing.
- Published
- 2018
- Full Text
- View/download PDF
48. Predicting the temporal activity patterns of new venues.
- Author
-
D'Silva K, Noulas A, Musolesi M, Mascolo C, and Sklar M
- Abstract
Estimating revenue and business demand of a newly opened venue is paramount as these early stages often involve critical decisions such as first rounds of staffing and resource allocation. Traditionally, this estimation has been performed through coarse-grained measures such as observing numbers in local venues or venues at similar places (e.g., coffee shops around another station in the same city). The advent of crowdsourced data from devices and services carried by individuals on a daily basis has opened up the possibility of performing better predictions of temporal visitation patterns for locations and venues. In this paper, using mobility data from Foursquare, a location-centric platform, we treat venue categories as proxies for urban activities and analyze how they become popular over time. The main contribution of this work is a prediction framework able to use characteristic temporal signatures of places together with k -nearest neighbor metrics capturing similarities among urban regions, to forecast weekly popularity dynamics of a new venue establishment in a city neighborhood. We further show how we are able to forecast the popularity of the new venue after one month following its opening by using locality and temporal similarity as features. For the evaluation of our approach we focus on London. We show that temporally similar areas of the city can be successfully used as inputs of predictions of the visit patterns of new venues, with an improvement of 41% compared to a random selection of wards as a training set for the prediction task. We apply these concepts of temporally similar areas and locality to the real-time predictions related to new venues and show that these features can effectively be used to predict the future trends of a venue. Our findings have the potential to impact the design of location-based technologies and decisions made by new business owners., Competing Interests: The authors declare that they have no competing interests.
- Published
- 2018
- Full Text
- View/download PDF
49. High-resolution mass spectrometry provides novel insights into products of human metabolism of organophosphate and brominated flame retardants.
- Author
-
Abdallah MA, Zhang J, Pawar G, Viant MR, Chipman JK, D'Silva K, Bromirski M, and Harrad S
- Subjects
- Animals, Hep G2 Cells, Humans, Rats, Bromine metabolism, Flame Retardants metabolism, Mass Spectrometry methods, Organophosphorus Compounds metabolism
- Abstract
The high resolution, accurate mass, and fast scanning features of the Orbitrap(TM) mass spectrometer, combined with the separation power of ultrahigh-performance liquid chromatography were applied for the first time to study the metabolic profiles of several organic flame retardants (FRs) present in indoor dust. To mimic real-life exposure, in vitro cultured HepG2 human hepatocyte cell lines were exposed simultaneously to various FRs in an indoor dust extract for 24 h. Target parent FRs, hexabromocyclododecanes (α-, β-, and γ-HBCDs), tris-2-chloroethyl phosphate (TCEP), tris(1-chloro-2-propyl) phosphate (TCIPP), and tris(1,3-dichloro-2-propyl) phosphate (TDCIPP), were separated in a single run for the first time using alternating positive and negative heated ESI source. Further metabolite separation and identification was achieved using full scan (70,000 full width at half maximum (FWHM)), accurate mass (up to 1 ppm) spectrometry. Structural confirmation was performed via all ion fragmentation (AIF) spectra using the optional higher collisional dissociation (HCD) cell and MS/MS analysis. First insights into human metabolism of HBCDs revealed several hydroxylated and debrominated phase I metabolites, in addition to conjugated phase II glucuronides. Furthermore, various hydroxylated, oxidized, and conjugated metabolites of chlorinated phosphorous FRs were identified, leading to the suggestion of α-oxidation as a significant metabolic pathway for these compounds.
- Published
- 2015
- Full Text
- View/download PDF
50. Effect of low versus high dialysate sodium concentration on blood pressure and endothelial-derived vasoregulators during hemodialysis: a randomized crossover study.
- Author
-
Inrig JK, Molina C, D'Silva K, Kim C, Van Buren P, Allen JD, and Toto R
- Subjects
- Aged, Blood Pressure physiology, Cross-Over Studies, Dialysis Solutions adverse effects, Endothelin-1 blood, Endothelium, Vascular metabolism, Female, Humans, Hypertension blood, Hypertension chemically induced, Hypertension prevention & control, Male, Middle Aged, Nitrites blood, Prospective Studies, Single-Blind Method, Sodium adverse effects, Treatment Outcome, Blood Pressure drug effects, Dialysis Solutions administration & dosage, Endothelium, Vascular drug effects, Renal Dialysis adverse effects, Sodium administration & dosage
- Abstract
Background: Intradialytic hypertension affects ∼15% of hemodialysis patients and is associated with increased morbidity and mortality. While intradialytic hypertension is associated with increases in endothelin 1 relative to nitric oxide (NO), the cause of these imbalances is unknown. In vitro evidence suggests that altering plasma sodium levels could affect endothelial-derived vasoregulators and blood pressure (BP). Thus, we hypothesized that compared to high dialysate sodium, low dialysate sodium concentration would lower endothelin 1 levels, increase NO release, and reduce BP., Study Design: 3-week, 2-arm, randomized, crossover study., Setting & Participants: 16 patients with intradialytic hypertension., Intervention: Low (5 mEq/L below serum sodium) versus high (5 mEq/L above serum sodium) dialysate sodium concentration., Outcomes: Endothelin 1, nitrite (NO2(-)), and BP., Measurements: Mixed linear regression was used to compare the effect of dialysate sodium (low vs high) and randomization arm (low-then-high vs high-then-low) on intradialytic changes in endothelin 1, NO2(-), and BP values., Results: The average systolic BP throughout all hemodialysis treatments in a given week was lower with low dialysate sodium concentrations compared with treatments with high dialysate sodium concentrations (parameter estimate, -9.9 [95% CI, -13.3 to -6.4] mm Hg; P < 0.001). The average change in systolic BP during hemodialysis also was significantly lower with low vs high dialysate sodium concentrations (parameter estimate, -6.1 [95% CI, -9.0 to -3.2] mm Hg; P < 0.001). There were no significant differences in intradialytic levels of endothelin 1 or NO2(-) with low vs high dialysate sodium concentrations., Limitations: Carryover effects limited the power to detect significant changes in endothelial-derived vasoregulators, and future studies will require parallel trial designs., Conclusions: Low dialysate sodium concentrations significantly decreased systolic BP and ameliorated intradialytic hypertension. Longer studies are needed to determine the long-term effects of low dialysate sodium concentrations on BP and clinical outcomes., (Copyright © 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.